Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

62 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-14

Study Completion Date

2021-08-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study was to assess the progression-free survival (PFS) based on local investigator assessment of pazopanib in participants with advanced and/or metastatic renal cell carcinoma (mRCC) following prior treatment with immune checkpoint inhibitors (ICI).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

NCT01235962

Renal Cell Carcinoma (RCC) Cancer

COMPLETED PHASE3

Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)

NCT02014636

Carcinoma, Renal Cell

COMPLETED PHASE1

Optimizing Pazopanib Exposure in RCC Patients

NCT02089802

Locally Advanced Renal Cell Carcinoma Metastatic Renal Cell Carcinoma

TERMINATED PHASE2

Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

NCT01622660

Bladder Cancer

TERMINATED PHASE2

Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma

NCT00334282

Carcinoma, Renal Cell

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This was a multi-center, open-label, single-arm Phase II study to determine the efficacy, tolerability, safety and quality of life of treatment with pazopanib in subjects with advanced and/or metastatic renal cell carcinoma (RCC) following prior treatment with immune checkpoint inhibitors (ICI).

Subjects could have received prior systemic therapy with an ICI (monotherapy or combination) as 1st or 2nd line RCC treatment. However, they must not have received pazopanib previously. In this study, pazopanib could be administered in the 2nd or 3rd line setting. The therapeutic line for individual subjects was assigned at the time of screening.

Subjects received 800 mg of pazopanib daily until disease progression, unacceptable toxicity, death, pregnancy, start of a new anti-neoplastic therapy, discontinuation at the discretion of the investigator or patient, lost to follow-up or end of study, whichever came first.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Renal Cell Carcinoma Metastatic Renal Cell Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pazopanib- 2nd line treatment

Participants received pazopanib as 2nd line treatment

Group Type EXPERIMENTAL

Pazopanib

Intervention Type DRUG

Participants received 800mg of pazopanib once daily orally. Pazopanib was supplied as aqueous film-coated tablets containing 200 mg or 400 mg.

Pazopanib- 3rd line treatment

Participants received pazopanib as 3rd line treatment

Group Type EXPERIMENTAL

Pazopanib

Intervention Type DRUG

Participants received 800mg of pazopanib once daily orally. Pazopanib was supplied as aqueous film-coated tablets containing 200 mg or 400 mg.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pazopanib

Participants received 800mg of pazopanib once daily orally. Pazopanib was supplied as aqueous film-coated tablets containing 200 mg or 400 mg.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed locally recurrent or metastatic predominantly clear cell renal cell carcinoma.
* Measurable disease based on RECIST 1.1 criteria
* Prior systemic therapy with an immune checkpoint inhibitor (monotherapy or combination) as 1st or 2nd line RCC treatment. Note: patients with prior mTOR inhibitor or TKI treatment as monotherapy or in combination with immune checkpoint inhibitor were allowed; however, treatment with immune checkpoint inhibitor (monotherapy or in combination) must have been the last treatment prior to study entry.
* Last dose of immune checkpoint inhibitor therapy received 4 or more weeks before start of study treatment
* Karnofsky performance status ≥70%.
* Potassium, sodium, calcium and magnesium within normal limits of the central laboratory

Exclusion Criteria

* Renal cell carcinoma without any clear (conventional) cell component
* History or evidence of central nervous system (CNS) metastases (patients with pretreated metastases were eligible under certain conditions)
* Prior treatment with pazopanib
* Prior treatment with bevacizumab that was not given in combination with immune checkpoint inhibitor therapy.
* Prior treatment with more than 2 lines of therapy (combination treatments were considered 1 line of therapy)
* Not recovered from toxicity from prior immune checkpoint inhibitor therapy. Recovery was defined as ≤ NCI-CTCAE Grade 1, except for liver function test levels which must be \<Grade 1.
* Disease recurrence less than 6 months from the last dose of prior neoadjuvant or adjuvant therapy (including VEGF-R TKI)
* Patients receiving prohibited concomitant medications that could not be discontinued or replaced by safe alternative medication at least 5 half-lives of the concomitant medication or 7 days, whichever was longer, prior to the start of pazopanib treatment.
* Administration of any investigational drug within 4 weeks prior to the first dose of study treatment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No